

Corrigendum: Catalytic site remodelling of the DOT1L methyltransferase by selective inhibitors

Wenyu Yu, Emma J. Chory, Amy K. Wernimont, Wolfram Tempel, Alex Scopton, Alexander Federation, Jason J. Marineau, Jun Qi, Dalia Barsyte-Lovejoy, Joanna Yi, Richard Marcellus, Roxana E. Iacob, John R. Engen, Carly Griffin, Ahmed Aman, Erno Wienholds, Fengling Li, Javier Pineda, Guillermina Estiu, Tatiana Shatseva, Taraneh Hajian, Rima Al-awar, John E. Dick, Masoud Vedadi, Peter J. Brown, Cheryl H. Arrowsmith, James E. Bradner & Matthieu Schapira

Nature Communications 3:1288 doi:10.1038/ncomms2304 (2012); Published 18 Dec 2012; Updated 21 May 2013

While this Article was undergoing peer review, Basavapathruni *et al.* published co-crystal structures of EPZ004777 and related compounds in complex with DOT1L, which are in agreement with our results. The paper should have been cited at the end of the Discussion section as reference 49.

49. Basavapathruni, A. *et al.* Conformational adaptation drives potent, selective and durable inhibition of the human protein methyltransferase DOT1L. *Chem. Biol. Drug Des.* **80**, 971–980 (2012).